文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

感染性休克中氢化可的松停药策略评估:一项回顾性队列研究

Evaluation of Hydrocortisone Discontinuation Strategies in Septic Shock: A Retrospective Cohort Study.
PubMed 文献 · Crit Care Explor · 2025-07-14
一句话结论在感染性休克患者中,与逐渐减量相比,突然停用氢化可的松与更低的血流动力学不稳定发生率相关,但氢化可的松总疗程是停药后血流动力学不稳定的最强独立预测因素。

该回顾性队列研究纳入五家内科和外科ICU的414例成人感染性休克患者,均接受至少48小时应激剂量氢化可的松(≥200 mg/d)。按停药策略分为突然停药组和逐渐减量组。逐渐减量组血流动力学不稳定发生率更高(29.2% vs. 12.9%,p<0.001),血糖异常更频繁(59.4% vs. 43.1%,p<0.001),氢化可的松使用时间更长(9.9 vs. 4.1天,p<0.001),机械通气时间(20 vs. 15天,p=0.014)和ICU住院时间(23 vs. 17天,p=0.008)更长。氢化可的松总疗程是停药后血流动力学不稳定的最强独立预测因素(调整OR 1.083,95%CI 1.025-1.145,p=0.004),与策略无关。作者认为需要前瞻性研究确定感染性休克的最佳停药策略。

要点

  • 在感染性休克成人患者中,逐渐减量组血流动力学不稳定发生率为29.2%,高于突然停药组的12.9%(p<0.001)。
  • 逐渐减量组血糖异常发生率59.4%,高于突然停药组的43.1%(p<0.001)。
  • 逐渐减量组氢化可的松使用时间为9.9天,长于突然停药组的4.1天(p<0.001)。
  • 氢化可的松总疗程是停药后血流动力学不稳定的最强独立预测因素(调整OR 1.083,95%CI 1.025-1.145,p=0.004),与停药策略无关。
  • 逐渐减量组机械通气时间20天 vs. 突然停药组15天(p=0.014),ICU住院时间23天 vs. 17天(p=0.008)。

适用人群与场景

  • 成人患者(≥18岁)
  • 感染性休克
  • 接受至少48小时应激剂量氢化可的松(≥200 mg/d)
  • 五家内科和外科ICU

诊断标准与关键阈值

  • 血流动力学不稳定定义为:在减量期间或氢化可的松停药后72小时内重新启动血管升压药

研究设计与关键结果

  • 研究类型:回顾性队列研究;样本量:414例;场所:五家内科和外科ICU(三级医院)
  • 分组:根据氢化可的松停药策略分为突然停药组和逐渐减量组
  • 主要终点:逐渐减量组血流动力学不稳定发生率29.2% vs. 突然停药组12.9%(p<0.001)
  • 次要终点:逐渐减量组血糖异常59.4% vs. 突然停药组43.1%(p<0.001)
  • 次要终点:逐渐减量组氢化可的松使用时间9.9天 vs. 突然停药组4.1天(p<0.001)
  • 次要终点:逐渐减量组机械通气时间20天 vs. 突然停药组15天(p=0.014)
  • 次要终点:逐渐减量组ICU住院时间23天 vs. 突然停药组17天(p=0.008)
  • 氢化可的松总疗程是停药后血流动力学不稳定的最强独立预测因素(调整OR 1.083,95%CI 1.025-1.145,p=0.004),与策略无关

证据类型、等级与局限

  • 证据类型:回顾性队列研究
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,虽然突然停用氢化可的松与较少的ICU相关不良事件相关,但氢化可的松疗程是感染性休克患者停药后血流动力学不稳定的主要影响因素。
  • 作者认为,需要前瞻性研究确定感染性休克的最佳停药策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: While corticosteroid administration in septic shock has been shown to reduce vasopressor requirements and accelerate shock reversal, the optimal discontinuation strategy remains unexplored.

OBJECTIVES: The purpose of this study was to assess whether rates of hemodynamic instability differ among patients with septic shock undergoing abrupt hydrocortisone discontinuation compared with gradual tapering.

DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study conducted in five medical and surgical ICUs at a tertiary care hospital, involving adult patients (≥ 18 yr) with septic shock who received at least 48 hours of stress-dose hydrocortisone (≥ 200 mg/d).

MAIN OUTCOMES AND MEASURES: The primary outcome was hemodynamic instability, defined as vasopressor reinitiation during tapering or within 72 hours of hydrocortisone discontinuation. Secondary outcomes included dysglycemia, duration of mechanical ventilation, ICU and hospital length of stay, and mortality.

RESULTS: Patients were grouped based on their hydrocortisone discontinuation strategy into abrupt and gradual tapering groups. A total of 414 patients were included in this evaluation. Gradual tapering was associated with higher rates of hemodynamic instability (29.2% vs. 12.9%; p < 0.001), more frequent dysglycemia (59.4% vs. 43.1%; p < 0.001), longer hydrocortisone use (9.9 vs. 4.1 d; p < 0.001), and extended mechanical ventilation (20 vs. 15 d; p = 0.014) and ICU stay (23 vs. 17 d; p = 0.008). Total hydrocortisone duration was the strongest independent predictor of post-discontinuation hemodynamic instability, regardless of strategy (adjusted odds ratio, 1.083; 95% CI, 1.025-1.145; p = 0.004).

CONCLUSIONS AND RELEVANCE: While abrupt hydrocortisone discontinuation was associated with fewer ICU-related adverse events, hydrocortisone duration was the primary factor influencing hemodynamic instability post-discontinuation among patients with septic shock. Prospective studies are needed to determine the optimal discontinuation strategy in septic shock.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. AlMubayedh HO, AlMehizia RA, Salam A, et al. Evaluation of Hydrocortisone Discontinuation Strategies in Septic Shock: A Retrospective Cohort Study. Crit Care Explor. 2025. PMID: 40658883. doi:10.1097/CCE.0000000000001290

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。